ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,747Medicare Part D Prescriptions Filled, Including Refills

Rank: 26 out of 623

$573K Total Retail Price of All Prescriptions

Rank: 27 out of 623

363 Patients Receiving at Least One Drug in Part D
92%Patients 65 Years and Older
32% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 363 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

12% of this provider’s 363 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

2% of this provider’s 8,112 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$66 was the average price of a prescription from this provider, compared to $66 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
AMLODIPINE BESYLATE 281 251 1 3
SIMVASTATIN 250 230 2 2
FUROSEMIDE 238 228 3 5
RAMIPRIL 220 190 4 79
LEVOTHYROXINE SODIUM 219 193 5 4
JANTOVEN 215 215 6 54
METOPROLOL TARTRATE 194 175 7 9
METFORMIN HCL 191 182 8 6
HYDROCODONE-ACETAMINOPHEN 182 152 S3 9 17
LISINOPRIL 176 169 10 1
PRAVASTATIN SODIUM 175 156 11 11
HYDROCHLOROTHIAZIDE 149 136 12 8
METOPROLOL SUCCINATE 146 146 13 13
SERTRALINE HCL 138 138 14 20
OMEPRAZOLE 130 120 15 7
DONEPEZIL HCL 128 128 16 27
ATORVASTATIN CALCIUM 119 95 17 10
RANITIDINE HCL 117 113 18 23
ZETIA 111 107 19 99
TRAMADOL HCL 103 93 20 15
ISOSORBIDE MONONITRATE ER 101 101 21 64
WARFARIN SODIUM 99 95 22 14
DIOVAN 98 98 23 48
POTASSIUM CHLORIDE 92 87 24 24
CITALOPRAM HBR 88 86 25 21
NAMENDA 84 84 26 47
ZOLPIDEM TARTRATE 80 56 27 22
TERAZOSIN HCL 79 79 28 108
CARBIDOPA-LEVODOPA 78 78 29 88
DIGOXIN 76 76 30 63
CLOPIDOGREL 73 73 31 34
VENLAFAXINE HCL ER 64 64 32 96
PREDNISONE 62 61 33 40
SPIRIVA 61 58 34 58
PLAVIX 59 58 35 46
OXYCODONE HCL 58 43 S2 36 30
ALLOPURINOL 58 54 36 44
GEMFIBROZIL 57 53 38 110
KETOCONAZOLE 57 56 38 182
CLONIDINE HCL 57 48 38 55
QUINAPRIL HCL 57 56 38 138
GABAPENTIN 55 49 42 18
FENTANYL 52 52 S2 43 76
TAMSULOSIN HCL 52 43 43 35
ADVAIR DISKUS 52 49 43 39
VERAPAMIL ER 50 50 46 104
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 25, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.